(IRVINE, Calif., January 11, 2005) – Last month, federal and state investigators concluded that Allergan, Inc.’s BOTOX® (botulinum toxin type A) was not involved in the cases of four patients suffering from botulism after receiving treatment at a clinic in Fort Lauderdale, Florida. The U.S. Food and Drug Administration (FDA), in collaboration with The Centers for Disease Control (CDC), continues as the lead responsible Agency for the ongoing investigation which has determined that these botulism cases resulted from the illegal administration, by an unlicensed physician, of extremely large and irregular amounts of an unlicensed and unapproved botulinum toxin obtained from a Northern California maker of raw research material. Although BOTOX® is not involved in this ongoing investigation, Allergan continues to provide assistance to authorities wherever possible. Fortunately, no additional cases of botulism related to the use of unlicensed and unapproved botulinum toxin have been reported to date.

In response to published comments of a director of the Palm Beach County Health Department, Douglas S. Ingram, Allergan’s Executive Vice President, said, “There is no question that the use of unlicensed and unapproved botulinum toxin is unlawful and dangerous. We have worked closely with the Florida Department of Health in investigating the isolated case of an unlicensed doctor in Florida using an unapproved bulk toxin and wholeheartedly support efforts to prevent this unlawful practice from continuing in the future.”

Ingram continued, “However, halting the use of BOTOX® and BOTOX® Cosmetic in South Florida is unnecessary and inappropriate. This investigation does not involve BOTOX® and it is not an issue of an unsuspecting health care practitioner getting something other than BOTOX®. The issue of unsafe alternatives to BOTOX® involves unethical health care professionals who, for reasons of greed and total disregard for their patients’ well-being, knowingly choose to use unlicensed, unapproved and dangerous products, rather than a real medicine, BOTOX®. Physicians and patients are able to confirm whether they are receiving authentic BOTOX® and BOTOX® Cosmetic prior to treatment by 1.) visiting only reputable and licensed physicians; and 2.) inspecting the vial of BOTOX® to be used to confirm that it displays the BOTOX® trademark and Allergan’s unique hologram.”

BOTOX® has been used for over 15 years to treat millions of patients worldwide for serious or debilitating neurological disorders. In addition, BOTOX® has a 15-year manufacturing history with rigorous quality control and quality assurance processes that are overseen by numerous health authorities worldwide. Physicians and patients should continue to feel confident in the heritage and safety record of authentic BOTOX® and BOTOX® Cosmetic.

To ensure receipt of authentic BOTOX® and BOTOX® Cosmetic, physicians and patients should know that:

· BOTOX® ­­ distributed under the names BOTOX® and BOTOX® Cosmetic ­ is the only licensed and FDA-approved botulinum toxin type A product available in the United States.

· Only licensed and skilled physicians should inject BOTOX® and BOTOX® Cosmetic. Optimal results are achieved when BOTOX® is administered by a well-trained physician with extensive knowledge of the product and the area of injection, and who has the qualifications necessary to evaluate and determine the best treatment for each individual.

· Allergan has a number of measures in place to ensure the integrity and authenticity of BOTOX® and BOTOX® Cosmetic, including a state-of-the-art holographic marking on each vial that is easy to inspect.

· Patients should always verify with their physicians that they are receiving authentic BOTOX® or BOTOX® Cosmetic and not an unlicensed botulinum toxin.

· Licensed products available in the U.S. can be verified by checking with the FDA’s web site at www.fda.gov. Physicians and consumers with questions may also call 1-800-433-8871 to speak to a company representative if they are unsure a product is the licensed and approved BOTOX® product.

Allergan encourages both physicians and consumers to visit its web sites at www.Allergan.com, www.BOTOX.com and www.BOTOXCosmetic.com to learn more about BOTOX® and BOTOX® Cosmetic.

About Allergan, Inc.

Allergan, Inc., with headquarters in Irvine, California, is a technology-driven, global health care company providing specialty pharmaceutical products worldwide. Allergan develops and commercializes products in the eye care, neuromodulator, skin care and other specialty markets that deliver value to its customers, satisfy unmet medical needs, and improve patients’ lives.

Allergan Contacts:

Jim Hindman (714) 246-4636 (investors)

Joann Bradley (714) 246-4766 (investors)

Ashwin Agarwal (714) 246-4582 (investors)

Caroline Van Hove (714) 246-5134 (media)

Stephanie Fagan (714) 246-5232 (media)

# # #